26 Jun 2023 – Nova MSC Berhad (“NovaMSC” or “the Group”), a leading provider of software development and engineering solutions, is pleased to announce the appointment of Dato’ Adriana Law (below left) and Nazerollnizam Kasim (below right) as members of its Board of Directors.

NovaMSC’s Executive Chairman, Mr Loh Guan Huat Sunny, warmly welcomed the new directors and said, “We are delighted to have Dato’ Adriana Law and Nazerollnizam Kasim joining our Board. Their diverse experience and innovative thinking will be crucial as we implement our strategy to drive growth across our four business units. I am confident they will substantially contribute to our Group’s transformation journey.”

Dato’ Adriana Law brings two decades of experience in event and exhibition management to the Board. She has held several senior leadership positions, including CEO roles at two Star Media Group companies. Her portfolio includes successfully managing and promoting the iOi Grand Exhibition & Convention Centre. Her expertise will be valuable as the Group aims to expand its outreach and engagement activities.

Meanwhile, Nazerollnizam Kasim, currently a General Manager at Nova MSC Berhad, has been a leading figure in the IT industry for the past 30 years. His experience encompasses diverse areas, from enterprise business applications to digital transformation and technology solutions that enhance operations across various industries. Mr. Kasim’s proven track record in leadership, management, and business application solutions will be instrumental in Nova MSC’s transformative journey.

Their appointment comes as part of Nova MSC’s strategic transformation and turnaround plan that focus on four of its key business units: Healthcare, E-Government, Robotics and Diagnostic.

According to Mr Loh, as the world recover from the negative effect of the COVID-19 situation, it is important for the Group to refocus on its core competencies and embrace new trends and innovation.

As part of the transformation plan, the Group is undertaking a thorough analysis of its operational structure, processes, and expenses to identify areas of cost rationalization and efficiency improvement. The Group aims to streamline operations, eliminate redundancies, and leverage technological advancements to achieve significant cost savings without compromising product quality or customer satisfaction.

In addition to cost rationalization, the Group is intensifying its efforts to drive sales and expand market outreach.  The recent signing of a memorandum of understanding with Theta Edge Berhad is an example of our effort to continuously look for opportunities to market and promote our healthcare, public sector and applied AI solutions in the regions.

The transformation plan also encompasses the adoption of innovative technologies. Our investment in AI and other technological advancements have begun to show remarkable results, bolstering the Group’s competitive edge and positioning it as a leader in the industry.  Combining cutting-edge hardware and software, Dex-lab Pte Ltd, a subsidiary of the Group, developed a human-looking social robot called DEXIE for the eldercare industry in Singapore.   To-date, it has been successfully sold in several nursing homes in Singapore to deliver positive interaction and engagement to the seniors through humanoid-facilitated therapeutic and activity programs, particularly for seniors with dementia.  Furthermore, the incorporation of DEXIE has shown to streamline processes, leading to increased productivity and efficiency for the nursing homes.

“We are excited to witness the initial positive outcomes from the deployment of DEXIE.” said Mr Loh. “The integration of these advanced technologies has not only improved our customer engagement and service but has also had a profound impact on our bottom line. We are proud to have taken this bold step towards innovation, and we believe that it sets us apart from our competitors.”

Meanwhile, EyRIS’ AI-driven SELENA+, a deep learning system that enables early detection of eye diseases such as diabetic retinopathy, glaucoma suspect and age-related macular degeneration, is taking big strides.  EyRIS will be partnering Optometrist Warehouse, part of Chemist Warehouse Group based in Australia on a ground-breaking study to focus on the effectiveness of using AI in screening diabetic retinopathy in Australia.

Please direct all queries related to this article to Marketing at


Comments are closed.